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Chronic airway diseases are categorized as a heterogeneous group of diseases with multiple phenotypes, that
are primarily based on the existence of inflammatory cell infiltration mechanisms. Interleukins are key players
in the pathogenesis of inflammation and in the propagation of chronic inflammatory airway diseases, such as,
chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, lung cancer and allergic asthma [1].
Interleukins are cytokines that are produced predominantly by the T cells. Understanding their mechanisms and
their roles in pathogenesis have increased their potential as possible targets for new treatments in chronic airway
diseases, employing advanced drug delivery methods [2].
In the cytokine family, interleukins form a major class of cell signaling molecules. Previously, they were thought
to be proteins, that were produced by leucocytes. It has now become apparent that they are formed by different cell
types with overlapping properties of pleiotropic nature. Helper CD4+ T lymphocytes, monocytes, macrophages
and endothelial cells produce most of the known interleukins. While interleukins are often named individually,
their families frequently include multiple groups. There are a total of 37 interleukins that are involved in major
chronic airway diseases like asthma and COPD [3].
Asthma, according to a recent study, may comprise of several forms, including allergic asthma and steroid-proof
asthma. It is well known that allergens activate mast cells, which lead to the inflammation of the airways, triggering
an acute inflammatory response in susceptible individuals. Dendritic cells that drive differentiation and secretion
of Th2 cytokines, such as IL-4, IL-5, IL-9, IL-13 and IL-17 recognize the allergens. Among these cytokines, IL-4
and IL-13 cause B cells to generate IgE, whereas, IL-13 induces the secretion of periostin by epithelial cells [4].
Furthermore, IL-9 causes hypersecretion of mucus by inducing the mast cells. IL-5 supports the development of
eosinophils, their recruitment and their survival. IL-17 acts on bronchial epithelial cells, whereby it stimulates the
release of CXCL8. These interleukins are also linked to airway hyper-responsiveness and remodeling [5].
COPD is attributed primarily to smoking, or any prolonged substantial exposure to smoke, dust or polluted air,
which eventually result in a range of pathological complications that include, chronic bronchial inflammation, lung
tissue damage and minor scarring. Cytokines, namely, TNF-α, IFN-γ, IL-1, IL-6, IL-8, IL-18 and IL-32 play a major
role in the activation of various inflammatory processes that involve, T cells, neutrophils and macrophages [3]. In
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addition, there are several studies that have reported the role of IL-17 in the pathogenesis of COPD [6]. Interleukins
have generated tremendous interest lately and have formed an integral part of evolving novel treatment strategies
that include the use of advanced drug delivery systems, in the management of inflammatory chronic respiratory
diseases.
Need for advanced drug delivery strategies
Interleukins are evolving treatment strategies in managing the chronic respiratory diseases inflammation, which
can be effectively target in managing disease pathology using the concept of advanced drug delivery systems. The
conventional pharmacotherapy for chronic airway diseases can be divided into several categories depending on
the type of therapeutic agent used. There are various chemical compounds, peptides, antibodies and genetic
factors that are employed in the treatment of chronic airway diseases (e.g., siRNA, shRNA and miRNA) [7].
Unfortunately, pharmacotherapy alone cannot completely and effectively cure chronic airway diseases. The only
existing treatment strategy adopted for asthma is the management of the symptoms. In addition, treatment
strategies for COPD currently involve, steroids, bronchodilators, pirfenidone and nintedanib; nevertheless, there
are no effective treatment modalities available for complete cure [8].
Emerging advanced nanoscale drug delivery strategies have shown promising results in the pharmacotherapy
of chronic respiratory diseases. Such advanced pharmaceuticals may boost the pharmacokinetic profile of loaded
therapy, based on their intrinsic physical properties. In addition, recent developments in nanocarriers with different
targeting motives may mitigate the impact of drugs on selective delivery to target cells [9,10]. Traditional drug therapies
often have limitations. The pharmacokinetic profile and low diffusion rates of conventional drug therapies often
result in a low therapeutic response. For example, in gene therapy, an efficient vector system is often required.
Apparently, gene molecules are not easily delivered in cells without carriers and are often degraded to biological
fluids. To overcome these issues, nano delivery devices have come up as promising carriers in recent decades [11,12].
Advanced drug delivery strategies that target interleukins
Recent reports have emphasized the potential applications of novel drug delivery systems in targeting chronic
airway diseases. Yong et al. demonstrated that quercetin loaded liquid crystalline nanoparticles (LCNs) may be
a therapeutic treatment for asthma, as important pro-inflammatory markers such as IL-1β, IL-6 and IL-8 have
been successfully suppressed and thus the anti-inflammatory activity of the drug may be significantly enhanced.
The improved anti-inflammatory activity of quercetin LCNs may likely be attributed to the properries of LCNs
themselves, which are bioadhesive in nature. They enhance the permeation of broncho-epithelial cell membranes
resulting in increased cellular uptake and drug absorption [13]. Another study reported the effectiveness of liposomal
curcumin in asthma at lower doses when compared with free curcumin. The combination effect of curcumin and
phospholipids had enabled the curcumin liposomes to suppress the pro-inflammatory markers (IL-6, IL-8, IL-1β
and TNF-α) in the BCi-NS1.1 cell line [14].
Several other studies have reported that the nanoparticle-based delivery of various drugs such as, dexamethasone,
andrographolide and budesonide has allowed a more effective inhibitory effect of Th2 cytokines, mainly, IL-
4 and IL-13, possibly because of enhanced bioavailability, better lung deposition and sustained release of the
drug [15–17]. Luo et al. have previously assessed the implications of nanovaccine with poly(lactic-co-glycolic) acid
(PLGA-ovalbumin [OVA] + A20 [ubiquitin E3 ligases]) on asthma allergy in a murine model. The study showed
that, the nanovaccine significantly increased the generation of Treg cell and IL-10, and eventually decreased airway
allergic response in sensitized mice [18]. Recent studies have further shown that silica dioxide and zinc oxide
nanoparticles have negative impacts on asthma exacerbation as they substantially increase mRNA expression levels
of inflammatory cytokines followed by an elevation in TXNIP, NLRP3 and IL-1β-proteins [19,20].
Conclusion
Chronic inflammation is a global issue and is largely advancing due to an aging population and a substantial rise
in air pollution from particulate matter over recent decades. Developing a more precise understanding of pro- and
anti-inflammatory cytokines that regulate and/or facilitate disease severity is important for developing advanced
therapeutics. Given the substantial progress in chronic inflammatory airway diseases, most of our clinical strategies
result in serious side effects. In this commentary, we have addressed advanced pharmaceutical drug therapies for
chronic airway diseases. Although, clinical applications of nanocarriers are still in their early stages; their applications
in the field of respiratory medicine and innovative nanomaterials are continuously being expedited. Despite the
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primary challenges, there may be highly reliable advanced options that deliver medical sciences and technological
advances in nanobiotechnology, which may lead to the effective management of chronic airway diseases.
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